FDA Clears AutoGenomics' CYP2C19 Assay | GenomeWeb

This article has been updated to clarify the intended use of the assay.

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – AutoGenomics today said that the US Food and Drug Administration has given 510(k) clearance for its Infiniti CYP2C19 assay.

The test detects three genetic variants, *2, *3, and *17 of the CYP450 2C19 gene. The test is for use on AutoGenomics' Infiniti Analyzer molecular diagnostic platform.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Theresa May tries to reassure researchers about the UK's commitment to science, New Scientist reports.

In Science this week: new single-cell RNA sequencing technique to study proliferating cells, and more.

South African researchers uncover bone cancer in an ancient hominin ancestor.

English bulldogs suffer from low genetic diversity and might have to be outbred to improve their health, according to a new study.